Alumis Inc. ALMS
6.50 USD +0.12 (+1.88%)
At closeNov 3, 2026, 5:48 PM EST
6.56 +0.06 +0.92%
After hours · Nov 3, 5:48 PM ET
6.22 Day range 6.61
4.40 52-week range 31.35
- YTD
- -33.40%
- 1 year
- +42.54%
- Market cap
- 841.33M
- Revenue (ttm)
- 7.40M
- EPS (ttm)
- -3.86
- Shares out
- 129.44M
- Forward P/E
- -2.82
- YTD return
- -33.40%
- 1-year return
- +42.54%
- Volume
- 2.56M
- Avg volume
- 2.67M
- Open
- 6.41
- Previous close
- 6.38
- Day's range
- 6.22 – 6.61
- 52-week range
- 4.40 – 31.35
- Beta
- -0.79
- Analysts
- Strong Buy
- Price target
- 32.13 (+394.2%)
- Earnings date
- Nov 12, 2026
2Y -4.92 (-43.08%)
Key statistics
- Enterprise value
- 556.67M
- PEG ratio
- 0.00
- Price / sales
- 141.89
- Price / book
- 2.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -37.70%
- Free cash flow
- -208.64M
- Total cash
- 502.29M
- Total debt
- 36.43M
- Return on equity
- -93.65%
- Short % of float
- 7.27%
- 50-day average
- 21.50
- 200-day average
- 22.28
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.13 +394.2% upside
Now 6.50
- Target (low)
- 15.00
- Target (mean)
- 32.13
- Target (high)
- 46.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.75.
Financials — quick view
ALMS Revenue — quarterly 1.66M
ALMS Net income — quarterly -142.22M
ALMS EPS — quarterly -1.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.73 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.767 | -1.11 | -0.34 | -44.72% |
| May 14, 2026 | Mar 31, 2026 | -0.74273 | -0.74 | 0.00 | +0.37% |
| Mar 19, 2026 | Dec 31, 2025 | -0.97 | -0.95 | +0.02 | +2.06% |
| Nov 13, 2025 | Sep 30, 2025 | -0.92 | -1.06 | -0.14 | -15.22% |
| Aug 13, 2025 | Jun 30, 2025 | -1.11 | -1.17 | -0.06 | -5.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 2026 | Guggenheim | down | Buy | Neutral |
| Sep 2, 2026 | Oppenheimer | main | Outperform | Outperform |
| Sep 2, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 2, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 2, 2026 | HC Wainwright & Co. | up | Neutral | Buy |
| Aug 14, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alumis.com
News
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 
Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026 
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures 
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis 
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review 
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS) 
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp 
Alumis to Participate in Upcoming September Investor Conferences 
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Your note
Sign in to keep a note on ALMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Purchase | Sep 7, 2026 | 0 |
| AYURMAYA CAPITAL MANAGEMENT COMPANY, LP | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 20, 2025 | 0 |
| BABLER MARTIN | Chief Executive Officer | Purchase | Mar 31, 2025 | 0 |
| BRADLEY MARK CHRISTOPHER | Officer | Sale | Aug 2, 2026 | 88,585 |
| DRAPPA JORN | Officer | Sale | Aug 2, 2026 | 56,892 |
| FORESITE CAPITAL MANAGEMENT VI, LLC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 7, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ayurmaya Capital Management Company, LP | 11.70% | 15,139,707 | 122.78M | Jun 29, 2026 |
| Blackrock Inc. | 6.35% | 8,218,151 | 66.65M | Jun 29, 2026 |
| FMR, LLC | 5.23% | 6,769,170 | 54.90M | Jun 29, 2026 |
| Deep Track Capital, Lp | 4.90% | 6,348,558 | 51.49M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 4.90% | 6,345,219 | 51.46M | Jun 29, 2026 |
| Foresite Capital Management V, LLC | 4.56% | 5,896,995 | 47.82M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.43% | 3,139,756 | 25.46M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.55% | 2,012,064 | 16.32M | Jul 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.06% | 1,369,916 | 11.11M | Jun 29, 2026 |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 0.84% | 1,088,300 | 8.83M | Jun 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 0.77% | 999,800 | 8.11M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 977,098 | 7.92M | Jun 29, 2026 |